Interferon-alpha therapy in atopic dermatitis.
Thirteen patients with a severe adult form of atopic dermatitis (AD) received 3.0 x 10(6) IU of recombinant interferon-alpha 2a (rIFN-alpha 2a) 3 times a week. A satisfactory response was obtained in 5 of them. Serum IgE levels in all 13 patients remained unchanged throughout the study. Flu-like symptoms were common, but clinical or laboratory adverse effects were otherwise slight. The moderately beneficial therapeutic effects observed in this study support a possible role for IFN-alpha in controlling immunologic deficiencies in atopic dermatitis.
Torrelo
A
A
Department of Dermatology, Hospital Ramón y Cajal, Madrid, Spain.
Harto
A
A
Sendagorta
E
E
Czarnetzki
B M
BM
Ledo
A
A
D000293:Adolescent; D000328:Adult; D003876:Dermatitis, Atopic / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007273:Injections, Intramuscular; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010865:Pilot Projects
D016898:Interferon-alpha; D007073:Immunoglobulin E